Novavax Stock Rises Despite No Confirmed News Behind the Matrix-M Rumor
Novavax is rising on investors reaction to an unconfirmed rumor that Matrix-M has a favorable safety profile with self-limiting side effects.
Stocks · News reference
Watching Novavax; Shares Trading Higher In The Session, Traders Circulate Unconfirmed Rumor Suggesting Clinical Data Show That Matrix-M Has A Favorable Safety Profile With Mostly Mild-To-Moderate, Self-Limiting Side Effects
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Novavax shares are trading higher. Strength may be due to an increase in investor attention related to an unconfirmed rumor suggesting that Matrix-M has a favorable safety profile with mostly mild-to-moderate, self-limiting side effects.
What's Going On With Novavax Stock?
Shares of Novavax are trading higher Tuesday. The stock is up over 30% over the trailing month as traders weigh updated autumn vaccine authorizations against the company's broader strategic pivot toward licensing and cost-structure optimization.